US2009264341A1PendingUtilityA1
Purified arabinogalactan-protein (agp) composition useful in the treatment psoriasis and other disorders
Est. expirySep 1, 2024(expired)· nominal 20-yr term from priority
A61P 37/08A61P 37/06A61P 29/00A61P 25/00A61P 19/02A61K 36/66A61P 17/04A61P 17/06A61P 11/00A61P 11/06A61P 1/04C07K 14/415Y02A50/30
58
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A purified Arabinogalactan-Protein (AGP) composition isolated through a selective method from the leaves and/or stems of Argemone mexicana plant is described. Also described is a purified Arabinogalactan-Protein (AGP) composition isolated from the leaves and/or stems of Argemone mexicana plant, which has one or more of the following effects: immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFN-γ inhibition, or IL-10 induction; keratinocyte proliferation inhibition, keratolytic activity and inhibitory activity in Mouse Ear Swelling test (MEST).
Claims
exact text as granted — not AI-modified1 - 58 . (canceled)
59 . A purified Arabinogalactan Protein (AGP) composition, having an average molecular weight range between 10 KD to 150 KD, isolated from the leaves, stems or both of Argemone mexicana plant.
60 . A pharmaceutical composition comprising a therapeutically effective amount of the purified Arabinogalactan Protein (AGP) of claim 59 and a pharmaceutically acceptable excipient.
61 - 89 . (canceled)Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.